Dr. Angelika Vlachou has been investing venture capital in biotech, pharma and life science start-ups for over 10 years. Over the course of her career, she has managed many transactions ranging from seed-stage venture capital and growth financing to licensing agreements, trade sale transactions and IPOs. Her expertise is also based on her virology-molecular biology research experience. One of her strengths is to combine scientific innovation with commercial potential. She is a valued sparring partner for founders, investors and stakeholders. With a doctorate in biology, she started her professional career in investment banking.
From Innovator to Entrepreneur
How to Finance a Company in the Seed Phase - Europe´s active seed investor wants to share insights about early stage financing Meet the VC experts - get feedback to your pitch and profit from the experience of 15+ years financing expertise
High-Tech Gründerfonds (HTGF) is Europe’s most active seed stage investor for highly innovative technologies across all sectors with a total of around 900 million euros under management in three fund generations. We invest in people, provide them with venture capital to implement their high-tech ideas and innovative business models. Investing in high-tech start ups is our passion. We understand our role in the start-up eco system by providing capital but also know-how and networks, especially in the early stages of a company´s development. We want to give scientists, researchers, founders and entrepreneurs, who want to start a business insights on how to finance a company, how to find the right investor, how to manage the financing process.
Feel free to send us your questions in advance to firstname.lastname@example.org we will be happy to answer them.
Join our 1:1 pitch session and get early feedback from the investment experts on your 5-minute pitch. You can ask all questions you might have, such as
What information is most relevant for an investor?
How to present information appropriately?
How to improve presentation skills
.. any other questions you might have on your mind!
Our experts look forward to giving you individual feedback on your pitch in exclusive 1:1 sessions. Profit from the experience of our team! Get in touch with us! We look forward to it.
PUBLIC DISCUSSION VIA LIVESTREAM AND ON-SITE AT THE BERLIN SCIENCE WEEK CAMPUS.
This event can be attended digitally via livestream or in-person with a limited on-site audience at the Museum of Natural History.
Livestream: Shortly before the event begins, the stream will be made available on this site. Add the event to your favourites and receive a reminder via email.
On-Site: If you would like to attend the event on-site, please book your spot via e-mail to: email@example.com
Due to the current situation, we are required to ask for the contact information of each person entering the Museum of Natural History in accordance with the Protection Against Infection Act. We therefore require the following data from all persons who register: First name, last name, address, telephone number and email address.
On-site the protective and hygienic measures of the Museum of Natural History apply. The so-called 3G rule (for “geimpft, genesen oder getestet“, i.e. “vaccinated, recovered or tested”) will be applied: Anyone who is not fully vaccinated or is not considered recovered will be required to provide a recent negative Covid-19 test. Visiting the event is permitted with a medical face mask only.
The registration data will be stored by the Hightech-Gründer Fonds for the purpose of organizing the event as well as for any subsequent contact follow-up and will also be shared with the organizers of Berlin Science Week and the Museum of Natural History for this purpose.
We will take pictures and videos on the Campus on 5/6 November, which we will use for documentation and communication purposes, and will livestream the events on our website. If you do not agree, please send your denial to via email to firstname.lastname@example.org prior to the Campus. We also refer to our data protection regulation.
Dr Frank Hensel holds a PH.D. in biology and has a longstanding experience as Entrepreneur in a Start-Up developing human monoclonal antibodies for cancer treatment. Since being part of HTGF in 2015 Frank built a solid portfolio of start-ups with a focus on drug development companies. Out of this portfolio 3 companies already entered the clinical stage and one company, Amal therapeutics, was successfully exited to Boehringer Ingelheim with a deal volume of up to 425Mio. €
Katharina Severin joined the Life Science Team as an Investment Analyst in September of 2021. She was born and raised in the Ruhr area and spent time in the US and Asia during her education. Among these stays was a one-year research stay in the lab of Tom Rapoport at Harvard Medical School in Boston. Katharina obtained her PhD in Medical Biology and received numerous scholarships and awards, among them stipends from the German National Academic Foundation and the Christiane Nüsslein-Volhard Foundation. Through networking opportunities from these foundations and as an attendee of the Lindau Nobel Laureate Meeting, Katharina discovered and cultivated her passion for interdisciplinary scientific exchange. Her research findings mark a starting point for a novel therapeutic approach in the treatment of cancer. Katharina is fascinated by entrepreneurial questions and is passionate about bringing scientific results and genious business ideas to profitable ventures.
Louis Heinz studied business administration, during which time he already got a taste of the start-up world. After graduating, Louis went into private equity and analysed established software and service companies. His enthusiasm for working with intelligent business models and highly motivated founders finally led him to High-Tech-Gründerfonds. Louis relishes every opportunity he gets, both at and outside of work, to put into practice the Russian language skills he acquired during several stays in Russia.
Berlin, Berlin 10115 Germany